Meeting
2020 Genitourinary Cancers Symposium
PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring FGFR3 alterations.
Authors
Sumanta K. Pal
City of Hope Comprehensive Cancer Center, Duarte, CA
Sumanta K. Pal , Siamak Daneshmand , Surena F. Matin , Yohann Loriot , Srikala S. Sridhar , Petros Grivas , Shilpa Gupta , Guru Sonpavde , Mark T. Fleming , Seth P. Lerner , Craig Berman , Jessica Rearden , Yining Ye , Hiywot Takkele , Susan Moran , Joaquim Bellmunt
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
EudraCT 2019-003248-63
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr TPS600)
Abstract #
TPS600
Poster Bd #
N18
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 alterations.
First Author: Siamak Daneshmand
Poster
2022 ASCO Genitourinary Cancers Symposium
Adjuvant infigratinib as targeted therapy for patients with muscle-invasive urothelial carcinoma harboring susceptible FGFR3 genetic alterations: A randomized, double-blind, placebo-controlled, phase 3 trial (PROOF 302).
First Author: Suzanne Cole
Poster
2023 ASCO Annual Meeting
Fibroblast growth factor receptor 3 (FGFR3) alterations in PROOF 302: A phase III trial of infigratinib (BGJ398) as adjuvant therapy in patients (pts) with invasive urothelial carcinoma (UC).
First Author: Petros Grivas
Poster
2023 ASCO Annual Meeting
A randomized, double blinded, multicenter phase 3 study of platinum-based chemotherapy with or without QL1706 as adjuvant therapy in completely resected stage II-IIIb NSCLC.
First Author: Yuming Zhu